Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects demand for infectious disease-related products in the Microbiology business to decline further in the coming fiscal year. In the Cell Processing business, it considers it highly likely that improving Japan-China relations will take time and is working to move away from a business structure that is highly susceptible to the effects of inbound demand and international relations.
Loss on disposal of fixed assets: ¥10.383 million; impairment loss on investment securities: ¥9.999 million; total extraordinary losses: ¥20.382 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥4,722 million（-4.4%） |
| Operating profit | Not disclosed → ¥137 million（-59.8%） |
| Ordinary income | Not disclosed → ¥147 million（-56.8%） |
| Profit attributable to owners of the parent | Not disclosed → ¥110 million（-55.9%） |
| Net income per share | Not disclosed → 21.65 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue: ¥4,939 million; operating profit: ¥341 million; ordinary profit: ¥340 million; net income attributable to owners of the parent: ¥251 million; earnings per share: ¥49.11 |
| Reason for the revision | The company expects demand for infectious disease-related products in the Microbiology business to decline further in the coming fiscal year. In the Cell Processing business, it considers it highly likely that improving Japan-China relations will take time and is working to move away from a business structure that is highly susceptible to the effects of inbound demand and international relations. |
| Details and amount of extraordinary loss | Loss on disposal of fixed assets: ¥10.383 million; impairment loss on investment securities: ¥9.999 million; total extraordinary losses: ¥20.382 million |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fiscal year ended March 2026, the Microbiology business experienced a decline in demand for products related to COVID-19 and influenza following the surge in demand for those products, while the Cell Processing business saw sluggish inbound patient numbers due to a decline in the number of visitors from China to Japan. For the fiscal year ending March 2027, the company expects demand for infectious disease-related products to decline further and states that improving Japan-China relations may take time.